ALK GENE REARRANGEMENT
Clinical trials for ALK GENE REARRANGEMENT explained in plain language.
Never miss a new study
Get alerted when new ALK GENE REARRANGEMENT trials appear
Sign up with your email to follow new studies for ALK GENE REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to fight lung cancer without chemo
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Lung cancer drug crizotinib tested as Post-Surgery shield
Disease control OngoingThis phase 3 trial tests whether the drug crizotinib can improve survival in people with early-stage non-small cell lung cancer that has a specific genetic change called ALK fusion. After surgery to remove the tumor, patients either take crizotinib pills or are simply observed. T…
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo attack on lung cancer: targeted drug plus surgery or radiation
Disease control OngoingThis early-phase trial is testing whether adding local treatments like surgery or radiation to the targeted drug brigatinib can help control advanced ALK-positive non-small cell lung cancer. About 35 people who have not yet taken other targeted therapies will receive brigatinib f…
Matched conditions: ALK GENE REARRANGEMENT
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC